ma research semaglutide reviews New is taking a closer look at what can happen a year or more after people stop taking GLP-1 medications. A systematic review published in the journal eClinicalMedicine examined 48 studies 📌 Editor's Choice from this

Systematic summarization of MBSH criteria allowed us to identify the predictors for MBSH, which can aid in early diagnosis and treatment, reducing the need for prolonged monitoring.

Explore its effects on fat loss, muscle preservation, and how to optimize your regimen for best results

Learn what the ads don't tell you, and how lifestyle medicine offers a more lasting path.

Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy (semaglutide 2.4mg), in Singapore

Fast UK dispatch from Astra Labs.

The 2.6 billion manufacturing investment complements the recent US manufacturing expansion for its next potential blockbuster obesity treatment orforglipron.